BRISBANE, Calif.--(BUSINESS WIRE)--XDx, Inc., a molecular diagnostics company focused on non-invasive gene expression tests for the monitoring of immune-mediated conditions, today announced the completion of enrollment for the Early Invasive Monitoring Attenuation Through Gene Expression (EIMAGE) clinical trial taking place at Cedars-Sinai Heart Institute, a leader in the field of heart failure and regenerative medicine.
